This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01863550
Recruitment Status : Active, not recruiting
First Posted : May 29, 2013
Last Update Posted : November 18, 2023
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group ( ECOG-ACRIN Cancer Research Group )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well they work compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether bortezomib, lenalidomide, and dexamethasone are more or less effective than carfilzomib, lenalidomide, and dexamethasone in treating patients with multiple myeloma

Condition or disease Intervention/treatment Phase
Plasma Cell Myeloma Drug: Bortezomib Drug: Carfilzomib Drug: Dexamethasone Other: Laboratory Biomarker Analysis Drug: Lenalidomide Other: Quality-of-Life Assessment Phase 3

Show Show detailed description
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1087 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Actual Study Start Date : December 6, 2013
Estimated Primary Completion Date : November 30, 2025
Estimated Study Completion Date : February 5, 2034

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Arm A (bortezomib, lenalidomide, dexamethasone)
Patients receive bortezomib SC or IV on days 1, 4, 8, and 11 of courses 1-8 and days 1 and 8 of courses 9-12; lenalidomide PO daily on days 1-14; and dexamethasone PO daily on days 1, 2, 4, 5, 8, 9, 11, and 12 of courses 1-8 and days 1, 2, 8, and 9 of courses 9-12. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.
 Drug: Bortezomib
Given SC or IV
Other Names:
  • [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid
  • LDP 341
  • MLN341
  • PS-341
  • PS341
  • Velcade

Drug: Dexamethasone
Given PO
Other Names:
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorene
  • Deronil
  • Desamethasone
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorene
  • Dexalocal
  • Dexamecortin
  • Dexameth
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Methylfluorprednisolone
  • Millicorten
  • Mymethasone
  • Orgadrone
  • Spersadex
  • Visumetazone

Other: Laboratory Biomarker Analysis
Optional correlative studies

Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • CC5013
  • CDC 501
  • Revlimid

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Experimental: Arm B (carfilzomib, lenalidomide, dexamethasone)
Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16; lenalidomide PO daily on days 1-21; and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 4 weeks for 9 courses in the absence of disease progression or unacceptable toxicity.
 Drug: Carfilzomib
Given IV
Other Names:
  • Kyprolis
  • PR-171

Drug: Dexamethasone
Given PO
Other Names:
  • Aacidexam
  • Adexone
  • Aknichthol Dexa
  • Alba-Dex
  • Alin
  • Alin Depot
  • Alin Oftalmico
  • Amplidermis
  • Anemul mono
  • Auricularum
  • Auxiloson
  • Baycuten
  • Baycuten N
  • Cortidexason
  • Cortisumman
  • Decacort
  • Decadrol
  • Decadron
  • Decalix
  • Decameth
  • Decasone R.p.
  • Dectancyl
  • Dekacort
  • Deltafluorene
  • Deronil
  • Desamethasone
  • Desameton
  • Dexa-Mamallet
  • Dexa-Rhinosan
  • Dexa-Scheroson
  • Dexa-sine
  • Dexacortal
  • Dexacortin
  • Dexafarma
  • Dexafluorene
  • Dexalocal
  • Dexamecortin
  • Dexameth
  • Dexamethasonum
  • Dexamonozon
  • Dexapos
  • Dexinoral
  • Dexone
  • Dinormon
  • Fluorodelta
  • Fortecortin
  • Gammacorten
  • Hexadecadrol
  • Hexadrol
  • Lokalison-F
  • Loverine
  • Methylfluorprednisolone
  • Millicorten
  • Mymethasone
  • Orgadrone
  • Spersadex
  • Visumetazone

Other: Laboratory Biomarker Analysis
Optional correlative studies

Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • CC5013
  • CDC 501
  • Revlimid

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Experimental: Arm C (lenalidomide)
Patients receive lenalidomide PO daily on days 1-21. Treatment repeats every 4 weeks for 24 courses in the absences of disease progression or unacceptable toxicity.
 Other: Laboratory Biomarker Analysis
Optional correlative studies

Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • CC5013
  • CDC 501
  • Revlimid

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment
Experimental: Arm D (lenalidomide)
Patients receive lenalidomide PO daily on days 1-21. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
 Other: Laboratory Biomarker Analysis
Optional correlative studies

Drug: Lenalidomide
Given PO
Other Names:
  • CC-5013
  • CC5013
  • CDC 501
  • Revlimid

Other: Quality-of-Life Assessment
Ancillary studies
Other Name: Quality of Life Assessment


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall survival (OS) for the maintenance analysis [ Time Frame: From the maintenance randomization to death due to any cause or, censored at the date last known alive, assessed up to 15 years ]
    The Kaplan-Meier (KM) method will be used to describe the overall survival function by arm. Sensitivity analysis will be done to evaluate OS in the subset of eligible patients and censoring patients at time of non-protocol therapy.

  2. Progression-free survival for the induction analysis [ Time Frame: From the induction randomization until the earlier of progression or death due to any cause, assessed up to 15 years ]
    The Kaplan-Meier method will be used to describe the progression-free survival function by arm using all data while ignoring maintenance.


Secondary Outcome Measures :
  1. Progression-free survival for the maintenance analysis [ Time Frame: From the maintenance randomization until the earlier of progression or death due to any cause, assessed up to 15 years ]
    Weighted Cox regression will be used.

  2. Overall survival for the induction analysis [ Time Frame: From induction randomization to death due to any cause, or censored at the date last known alive, assessed up to 15 years ]
    The KM method will be used.

  3. Response rates including partial response (PR), very good partial response (VGPR), immunofixation negative complete response (IF-CR) and complete response (CR) [ Time Frame: At 2.8 months ]
    Will be compared between induction arms using Fisher?s exact test.

  4. Response rates including PR, VGPR, IF-CR and CR [ Time Frame: At 8.3 months ]
    Will be compared between induction arms using Fisher?s exact test.

  5. Time to progression (TTP) for the induction analysis [ Time Frame: From the induction randomization to progression, or censored at the date of last disease evaluation for those without progression reported, assessed up to 15 years ]
    TTP distributions will be estimated by induction arm using Kaplan-Meier methods.

  6. Duration of response (DOR) for the induction analysis [ Time Frame: From first objective response (partial response or better) since induction randomization until the earlier of progression or death due to any cause, or censored at date of last disease evaluation for those without events reported, assessed up to 15 years ]
    Duration of response will be estimated using Kaplan-Meier methods in the subset of patients achieving partial response or better while on induction therapy.

  7. Incidence of overall grade 3 or higher non-hematologic toxicity and grade 3 or higher toxicity by type during induction, active maintenance and observation phases using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: Up to 15 years ]
    Fisher?s exact test will be used.

  8. Incidence of grade 2 or higher peripheral neuropathy and cardiac toxicity during induction phase assessed using CTCAE version 5.0 [ Time Frame: Up to 36 weeks ]
    Fisher?s exact test will be used.

  9. Minimal residual disease (MRD) negative rates [ Time Frame: At 8.3 months after induction randomization ]
    MRD evaluation by multiparametric flow cytometry will be conducted and patients classified as MRD negative, MRD positive or not evaluable. At each time point, MRD negative rates with two-sided 95% exact confidence intervals on each arm will be estimated. Patterns of change over time in MRD will also be evaluated using longitudinal regression analysis with general linear mixed effects models and GEE semi-parametric models. MRD negative rates will be compared between either induction or maintenance arms depending on the assessment time point using the Mantel-Haenszel test stratified either on intent to transplant at progression or induction arm (Step 1 and 2 stratification factors, respectively).

  10. Change in the Functional Assessment of Cancer Therapy-Neurotoxicity Trial Outcome Index (FACT-Ntx TOI) for the transition to maintenance analysis [ Time Frame: From week 36 (the end) of induction therapy to week 24 (end of course 6) of maintenance therapy ]
    Will be analyzed using linear mixed models.

  11. Change in the FACT-Ntx TOI for the short-term maintenance analysis [ Time Frame: From the end of 2 years of maintenance to 3 years post maintenance randomization ]
    Will be analyzed using linear mixed models.

  12. Change in the FACT-Ntx TOI for the long-term maintenance analysis [ Time Frame: From the end of 2 years of maintenance to 5 years post maintenance randomization ]
    Will be analyzed using linear mixed models.

  13. Change in the FACT-Ntx TOI for the end of induction analysis [ Time Frame: From baseline (induction randomization) to 36 weeks (end) of induction therapy ]
    Will be analyzed using linear mixed models.

  14. Change in the FACT-Ntx TOI for the early induction analysis [ Time Frame: From baseline (induction randomization) to 2.8 months of induction therapy ]
    Will be analyzed using linear mixed models.

  15. Levels and changes in the FACT-Ntx TOI and Functional Assessment of Cancer Therapy- Multiple Myeloma (FACT-MM) during induction, active maintenance and observation phases [ Time Frame: Up to 15 years ]
    Will be analyzed using linear mixed models.

  16. Time to worsening of FACT-Ntx TOI for the induction analysis [ Time Frame: From the baseline assessment at induction randomization to a decrease of 7 points, assessed up to 15 years ]
    Will be analyzed with KM methods and Cox regression.

  17. Time to worsening of FACT-MM for the maintenance analysis [ Time Frame: From the baseline assessment at maintenance randomization to a decrease of 4 points, assessed up to 15 years ]
    Will be analyzed with KM methods and Cox regression.


Other Outcome Measures:
  1. MRD negative rates [ Time Frame: At 2.8 months after induction randomization ]
    MRD evaluation by multiparametric flow cytometry will be conducted and patients classified as MRD negative, MRD positive or not evaluable. At each time point, MRD negative rates with two-sided 95% exact confidence intervals on each arm will be estimated. Patterns of change over time in MRD will also be evaluated using longitudinal regression analysis with general linear mixed effects models and GEE semi-parametric models. MRD negative rates will be compared between either induction or maintenance arms depending on the assessment time point using the Mantel-Haenszel test stratified either on intent to transplant at progression or induction arm (Step 1 and 2 stratification factors, respectively).

  2. MRD negative rates [ Time Frame: At 2 years after maintenance randomization ]
    MRD evaluation by multiparametric flow cytometry will be conducted and patients classified as MRD negative, MRD positive or not evaluable. At each time point, MRD negative rates with two-sided 95% exact confidence intervals on each arm will be estimated. Patterns of change over time in MRD will also be evaluated using longitudinal regression analysis with general linear mixed effects models and GEE semi-parametric models. MRD negative rates will be compared between either induction or maintenance arms depending on the assessment time point using the Mantel-Haenszel test stratified either on intent to transplant at progression or induction arm (Step 1 and 2 stratification factors, respectively).

  3. MRD negative rates [ Time Frame: At 3 years after maintenance randomization ]
    MRD evaluation by multiparametric flow cytometry will be conducted and patients classified as MRD negative, MRD positive or not evaluable. At each time point, MRD negative rates with two-sided 95% exact confidence intervals on each arm will be estimated. Patterns of change over time in MRD will also be evaluated using longitudinal regression analysis with general linear mixed effects models and GEE semi-parametric models. MRD negative rates will be compared between either induction or maintenance arms depending on the assessment time point using the Mantel-Haenszel test stratified either on intent to transplant at progression or induction arm (Step 1 and 2 stratification factors, respectively).

  4. Change in mutation status [ Time Frame: Baseline up to 15 years ]
    Descriptive statistics (absolute frequencies, percentages, mean, standard deviation [SD], median, range) will be used to characterize the study cohort by mutation incidence and expression levels at all time-points.

  5. Change in gene expression levels [ Time Frame: Baseline up to 15 years ]
    Descriptive statistics (absolute frequencies, percentages, mean, SD, median, range) will be used to characterize the study cohort by mutation incidence and expression levels at all time-points. Association of genotype data (binary) with categorical baseline patient and disease characteristics will be evaluated using chi-squared test or, if appropriate, Cochran-Armitage trend test. The Wilcoxon-rank sum test or, if appropriate, the Jonckheere-Terpstra test for trend will be used to assess differential expression levels with baseline patient and disease characteristic groups. The Kaplan-Meier method will be used to estimate progression-free and overall survival distributions and Cox regression to estimate hazard ratios by genotype status.

  6. Circulating plasma cells and plasma cell proliferation [ Time Frame: Up to 15 years ]
    With samples submitted pre-registration, multiparametric flow cytometry will quantify circulating plasma cells (cPC) in terms of number of clonal events/150,000 collected total events and plasma cell proliferation in terms of the plasma cell labeling index (PCLI) percentage. The Kaplan-Meier method will be used to estimate induction progression-free survival and overall survival distributions and Cox regression used to estimate hazard ratios by dichotomized cPC and PCLI.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • STEP I: Patients must be diagnosed with symptomatic standard-risk multiple myeloma (SR-MM) as defined by all of the following (except gene expression profile [GEP]70 status if unknown):

    • No evidence of t(14;16) by fluorescence in situ hybridization (FISH) testing on bone marrow or not available
    • No evidence of t(14:20) by FISH testing on bone marrow or not available
    • No evidence of deletion 17p by FISH testing on bone marrow

    • FISH should be from within 90 days of registration

      • NOTE: If the FISH result states that no immunoglobulin heavy chain (IgH) abnormality is present, both t(14;16) and t(14;20) can be considered negative; in addition, if the patient has a t(11;14) or t(4;14) translocation present, they can be considered negative for t(14;16) and t(14;20); if testing for t(14;16) or t(14;20) could not be performed for lack of sufficient material or non-availability of the probe in the test panel, patients can be enrolled on the study

    • Standard Risk GEP70 signature within the past 90 days (only if GEP has been done and results are available)

      • NOTE: GEP testing is NOT a requirement for the study; if the test has been done, patients found to have a GEP70 status of high-risk will not be eligible
    • Serum lactate dehydrogenase (LDH) =< 2 x upper limit of normal (ULN) within the past 28 days

    • No more than 20% circulating plasma cells on peripheral blood smear differential or 2,000 plasma cells/microliter on white blood cell (WBC) differential of peripheral blood within the past 90 days

      • NOTE: This is NOT the plasma cell % from the marrow aspirate

  • STEP I: Patients must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization:

    • >= 1 g/dL monoclonal protein (M-protein) on serum protein electrophoresis
    • >= 200 mg/24 hours (hrs) of monoclonal protein on a 24 hour urine protein electrophoresis
    • Involved free light chain >= 10 mg/dL or >= 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (< 0.26 or > 1.65)
    • Monoclonal bone marrow plasmacytosis >= 30% (evaluable disease)

    • Serum protein electrophoresis (SPEP), urine protein electrophoresis (UPEP), and serum free light chain (FLC) assay are required to be performed within 28 days prior to randomization; a bone marrow biopsy and/or aspirate is required within 28 days if bone marrow is being followed for response

      • NOTE: UPEP (on a 24-hour collection) is required, no substitute method is acceptable; urine must be followed monthly if the baseline urine M-spike is >= 200 mg/24 hr; please note that if both serum and urine M-components are present, both must be followed in order to evaluate response
      • NOTE: The serum free light chain test is required to be done if the patient does not have measurable disease in the serum or urine; measurable disease in the serum is defined as having a serum M-spike >= 1 g/dL; measurable disease in the urine is defined as having a urine M-spike >= 200 mg/24 hr
  • STEP I: Hemoglobin >= 8 g/dL (obtained within 28 days prior to randomization)
  • STEP I: Untransfused platelet count >= 75,000 cells/mm^3 (obtained within 28 days prior to randomization)
  • STEP I: Absolute neutrophil count >= 1000 cells/mm^3 (obtained within 28 days prior to randomization)
  • STEP I: Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior to randomization)
  • STEP I: Bilirubin =< 1.5 mg/dL (obtained within 28 days prior to randomization)
  • STEP I: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) and serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) < 2.5 times the upper limit of normal (obtained within 28 days prior to randomization)
  • STEP I: Patients must have received no more than one cycle (4 weeks or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma; they should not have been exposed to lenalidomide, bortezomib or carfilzomib for treatment of symptomatic myeloma; prior radiation therapy to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirements
  • STEP I: Prior systemic glucocorticoid use for the treatment of non-malignant disorders is permitted; prior or concurrent topical or localized glucocorticoid therapy to treat non-malignant comorbid disorders is permitted
  • STEP I: Patients must not have active, uncontrolled seizure disorder; patients must have had no seizures in the last 6 months
  • STEP I: Patients must not have uncontrolled intercurrent illness including uncontrolled hypertension, symptomatic congestive heart failure, unstable angina, uncontrolled cardiac arrhythmia, uncontrolled psychiatric illness or social situation that would limit compliance with the study, or a prior history of Stevens Johnson syndrome
  • STEP I: Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2 (performance status [PS] 3 allowed if secondary to pain)
  • STEP I: Patients with monoclonal gammopathy of undetermined significance or asymptomatic multiple myeloma are not eligible
  • STEP I: Patients must not have grade 2 or higher peripheral neuropathy by Common Terminology Criteria for Adverse Events (CTCAE) 4.0
  • STEP I: Patients must not have active, uncontrolled infection
  • STEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
  • STEP I: Patients should not have New York Heart Association classification III or IV heart failure or myocardial infarction within the previous 6 months
  • STEP I: Patients with a history of prior malignancy are eligible provided they were treated with curative intent and do not require active therapy (currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma ?in situ? of the cervix or breast are not excluded)

  • STEP I: Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide throughout the entire duration of study treatment, and for 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure; female subjects must agree to use contraception or abstinence for 30 days after last dose of carfilzomib

    • A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months
  • STEP I: Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 28 days after stopping lenalidomide; male subjects must also agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from lenalidomide; male subjects must be willing to use condoms for 90 days after discontinuation of carfilzomib

  • STEP I: The following patients will be excluded:

    • Pregnant women
    • Nursing women

  • STEP I: Human immunodeficiency virus (HIV) infection is not excluded; known HIV positive patients must meet the following criteria:

    • Cluster of differentiation (CD)4 cell count >= 350/mm^3
    • No history of acquired immune deficiency syndrome (AIDS)-related illness
    • Not currently prescribed zidovudine or stavudine
  • STEP I: Patient enrolling to this study must agree to register to the mandatory RevAssist program, and be willing and able to comply with the requirements of RevAssist
  • STEP II: Patients must have complete induction without experiencing progression or patients must have received at least 6 cycles on Arm A and 4 cycles on Arm B but stopped induction therapy due to adverse events
  • STEP II: Step 2 registration must be within 6 weeks of completing step 1 therapy
  • STEP II: Patients must not have received any non-protocol therapy outside of the assigned induction therapy including stem cell transplant
  • STEP II: ECOG performance status 0, 1, or 2 (PS 3 allowed if secondary to pain)
  • STEP II: Any adverse event related to step 1 therapy must have resolved to grade 2 or less
  • STEP II: Hemoglobin >= 8 g/dL (within 28 days prior to randomization to Step II)
  • STEP II: Platelet count >= 75,000 cells/mm^3 (within 28 days prior to randomization to Step II)
  • STEP II: Absolute neutrophil count >= 1000 cells/mm^3 (within 28 days prior to randomization to Step II)
  • STEP II: Calculated creatinine clearance >= 30 mL/min (within 28 days prior to randomization to Step II)
  • STEP II: Bilirubin =< 1.5 mg/dL (within 28 days prior to randomization to Step II)
  • STEP II: SGPT (ALT) and SGOT (AST) < 2.5 times the upper limit of normal (within 28 days prior to randomization to Step II)

  • STEP II: Females of childbearing potential (FCBP)* must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10-14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 28 days before she starts taking lenalidomide throughout the entire duration of study treatment, and for 28 days after the last dose of lenalidomide; FCBP must also agree to ongoing pregnancy testing; all patients must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure

    • A female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months
  • STEP II: Sexually active males must be willing to use a condom (even if they have undergone a prior vasectomy) while having intercourse, while taking lenalidomide and for 28 days after stopping lenalidomide; male subjects must also agree to abstain from donating blood, semen, or sperm during study participation and for at least 28 days after discontinuation from lenalidomide; males must agree to use contraception and agree to not donate sperm for at least 90 days after the last day of carfilzomib

  • STEP II: The following patients will be excluded:

    • Pregnant women
    • Nursing women
  • STEP II: Patient enrolling to this study must agree to register to the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01863550


Locations
Show Show 920 study locations
Sponsors and Collaborators
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Shaji Kumar ECOG-ACRIN Cancer Research Group
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: ECOG-ACRIN Cancer Research Group
ClinicalTrials.gov Identifier: NCT01863550    
Other Study ID Numbers: E1A11
NCI-2012-02608 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
ECOG-E1A11
E1A11
s17-00040
E1A11 ( Other Identifier: ECOG-ACRIN Cancer Research Group )
E1A11 ( Other Identifier: CTEP )
U10CA180820 ( U.S. NIH Grant/Contract )
U10CA021115 ( U.S. NIH Grant/Contract )
U24CA196172 ( U.S. NIH Grant/Contract )
First Posted: May 29, 2013    Key Record Dates
Last Update Posted: November 18, 2023
Last Verified: November 2023
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
 Dexamethasone acetate
Lenalidomide
Bortezomib
Ichthammol
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal